Unlocking the potential of CHK1: Discovery of BBI-355, the First ecDNADirected Therapy (ecDTx) for the Treatment of Oncogene Amplified Cancers
Time: 1:30 pm
day: Day Two
Details:
• Addressing unmet need of oncogene driven cancers
• Development of CHK1 inhibitor to disrupt cell cycle and cell survival in tumors
